The Morning Brief

The Economic Times
  • 4.5 (6)
  • BUSINESS NEWS

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

  1. The Chinese Cancer Fix

    21 HRS AGO

    The Chinese Cancer Fix

    A quiet revolution is underway in Indian oncology. Chinese-origin cancer drugs, brought to India through a growing number of pharma partnerships, are dramatically cutting the cost of immunotherapy — making treatment accessible to patients who previously had no options. Doctors are prescribing them, patients are responding well, and Indian companies — from Glenmark to Dr Reddy’s to Intas — are signing billion-dollar deals to expand access further. Western immunotherapy can cost up to five lakh rupees per session. Chinese-origin alternatives are bringing that down to fifty thousand. This episode explores how the India-China pharma axis is reshaping who gets treated, and how. See omnystudio.com/listener for privacy information.

    13 min
  2. Mythos and the New AI Cyber Panic

    2D AGO

    Mythos and the New AI Cyber Panic

    When an AI system can autonomously find and exploit vulnerabilities at scale — who controls the risk? In this episode of The Morning Brief, host Anirban Chowdhury sits down with Gary Marcus, AI expert, scientist and author to examine Anthropic's Mythos — a frontier AI system built for defensive cybersecurity that has rattled governments, central banks, and security researchers worldwide. The conversation unpacks why the dual-use dilemma at Mythos's core is so difficult to resolve, how India's financial and digital infrastructure sits squarely in the line of fire, and what RBI, MeitY, and Indian banks are quietly preparing for. From Anthropic's Project Glasswing to the limits of regulatory readiness, the episode probes whether the institutions meant to protect us are moving fast enough — and whether a defensive tool, in the wrong hands, is a defensive tool at all.Listen in:You can follow Anirban Chowdhury on his social media: X and Linkedin Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard, From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more. Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube. See omnystudio.com/listener for privacy information.

    19 min
  3. India's Biggest Trade Partner Is China. Now what?

    3D AGO

    India's Biggest Trade Partner Is China. Now what?

    China just surpassed the US as India's largest trading partner, with bilateral trade hitting $151 billion and a trade deficit that has ballooned to an all-time high of $112 billion. Beijing has also rolled out sweeping new supply chain rules that could penalise companies moving manufacturing out. So what does this mean for India? John Quelch, American President, Executive Vice Chancellor and Distinguished Professor of Social Science, Duke Kunshan University argues the deficit isn't the real story. China plays a long, calculated game — on tariffs, on technology, on geopolitics. India needs to learn to read that game, not react to it. From the Trump-Xi summit to robots, rare earths, and the untapped potential of two ancient civilisations — this conversation reframes everythingListen in:You can follow Anirban Chowdhury on his social media: X and LinkedinCheck out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, Two Women Fought to Change India's Maternity Laws...and Succeeded, Can India Truly End Naxalism?, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more. Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube. See omnystudio.com/listener for privacy information.

    18 min
  4. Polls on my Pod: Bengal Flips, Vijay Disrupts, Kerala Resets

    6D AGO

    Polls on my Pod: Bengal Flips, Vijay Disrupts, Kerala Resets

    A political script has been torn up across India’s key states. Tamil Nadu sees actor Vijay’s TVK disrupt decades of Dravidian dominance. West Bengal delivers a stunning power shift as BJP ends a 15-year Trinamool rule. Assam doubles down on continuity, handing Himanta Biswa Sarma a third term and deepening BJP’s hold. And Kerala returns to its classic anti-incumbency cycle, giving Congress a crucial win. In this episode of Polls on My Pod, Nidhi Sharma and ET's Dia Rekhi, Kumar Anshuman and CL Manoj decode the deeper story—fracturing vote banks, new social coalitions, and what these mandates signal for national politics ahead. Listen in: See omnystudio.com/listener for privacy information.

    26 min
  5. How Guneet Monga Rewrote Bollywood's Rules and Won an Oscar Doing It

    6D AGO

    How Guneet Monga Rewrote Bollywood's Rules and Won an Oscar Doing It

    She grew up navigating a war zone of a family home, arrived in Bombay with ₹50 lakhs borrowed from a neighbour, and watched her debut film get pulled from theatres the morning after India lost the cricket World Cup. That's where most stories end. Guneet Monga's was just beginning. In this candid, far-ranging conversation with ET’s Anirban Chowdhury and in-house film journalist and critic Rajesh N Naidu, the Oscar-winning producer and CEO of Sikhya Entertainment traces a 20-year journey defined by jugaad, grit, and an unshakeable belief in the power of story. From Gangs of Wasseypur to The Lunchbox, Kill to Women in Film India — this is the real education they don't teach at film school.You can follow Rajesh Naidu on: X and Linkedin & Anirban Chowdhury on his social media: X and LinkedinCheck out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, Two Women Fought to Change India's Maternity Laws...and Succeeded, Can India Truly End Naxalism?, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more.   Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube. See omnystudio.com/listener for privacy information.

    43 min

  6. MAY 3

    Guns, Glamour & Girl Bosses

    She’s dressed in designer labels at a high-profile party. She runs a beauty parlour in northeast Delhi. She has a pistol in one hand and a social media following in the other. Meet India’s new women gangsters — educated, visible, and deeply embedded in the country’s most feared criminal networks. From Rajasthan to Delhi to gang bosses operating out of Portugal, this is a story about crime, glamour, broken homes, and a society in rapid transition. ET Deep Dive, based on Shantanu Nandan Sharma’s ground report, goes inside the world they’ve built. Anirban Chowdhury narrates. See omnystudio.com/listener for privacy information.

    11 min
  7. AAP’s Breaking Point: The Exit of Seven

    MAY 1

    AAP’s Breaking Point: The Exit of Seven

    Seven Rajya Sabha MPs quitting together is a structural rupture inside Aam Aadmi Party.  From Raghav Chadha’s distancing to the exit of key organisational architects like Sandeep Pathak, this episode traces how AAP moved from a high-moral insurgency in 2015 to a party battling credibility, governance questions, and leadership centralisation.  Anirban Chowdhury and ET’s Nidhi Sharma examine its real delivery—schools, clinics, welfare—alongside its biggest missteps: Sheeshmahal, Yamuna, and the excise policy.  With Punjab now its last stronghold, the question is stark: can AAP still course-correct, or is this the beginning of a slow political unravelling? Tune in Credit: Hindustan Times See omnystudio.com/listener for privacy information.

    21 min
  8. Sun–Organon: The scope, risks, and future of India's biggest pharma deal

    APR 30

    Sun–Organon: The scope, risks, and future of India's biggest pharma deal

    India's largest drugmaker, Sun Pharma, has announced the acquisition of US-based Organon in a landmark $11.75 billion all-cash deal, the biggest overseas purchase by an Indian company since Tata-Corus in 2007. The move effectively doubles Sun Pharma's size, vaulting it into the top 25 global pharmaceutical companies with combined revenues of $12.4 billion. Host Anirban Chowdhury talks to ET's pharma expert Vikas Dandekar and associate editor Arijit Barman about why this deal gives Sun Pharma an instant foothold in biosimilars, a dominant position in global women's health, and a portfolio of established brands across 150 countries. With $2.5 billion in combined pre-financing free cash flows, the company looks well-positioned to tackle Organon's inherited debt burden. See omnystudio.com/listener for privacy information.

    17 min
See All (951)

Hosts & Guests

Ratings & Reviews

4.5
out of 5
6 Ratings

About

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

Information

More From The Economic Times

You Might Also Like